openPR Logo
Press release

Anergis Closes CHF 18 Million Series A Financing Round to Develop its Innovative Allergy Vaccines and Expands its Board of Directors

03-28-2011 04:47 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Anergis SA

/ PR Agency: akampion
LAUSANNE, Switzerland – March 28th, 2011 – Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.

Anergis SA is a clinical-stage biopharmaceutical company developing innovative immunotherapies against allergies. Its lead product, called “AllerT” and made of so-called Contiguous Overlapping Peptides (COPs), is designed to provide ultra-fast and safe desensitization to birch pollen allergy, a widely spread condition in developed countries.

The financing round was co-led by three major European funds with extensive biotech experience: Vinci Capital-Renaissance PME (Lausanne, Switzerland), BioMedInvest (managed by BioMedPartners AG, Basel, Switzerland) and Sunstone Capital (Copenhagen, Denmark). The syndicate was also joined by Esperante (Limhamn, Sweden), Initiative Capital Romandie (Lausanne, Switzerland) and by private investors. Up until now, Anergis has invested CHF 3 million in its innovative allergy vaccines. These funds were raised from private investors and from a grant by the Swiss Innovation Fund (CTI).

The newly joining investors also bring substantial pharmaceutical experience and know-how to Anergis: Patrick Scherrer (representing Vinci Capital-Renaissance PME), Markus Hosang (representing BioMedInvest) and Sten Verland (representing Sunstone Capital) have joined the Anergis Board of Directors. The Board will be chaired by André J. Mueller, a professional with unique executive and non-executive experience in biotech ventures, which he gained with Biogen and Actelion and as the Chairman of the Boards of Cerenis Therapeutics (Toulouse) and Addex Pharmaceuticals (Geneva).

“The proceeds of this financing will cover our financial requirements for the next two years and will allow us to take essential steps for the development of Anergis. In particular, we will now conduct a large Phase II multicenter trial with AllerT, our lead product for patients allergic to birch pollen, and we will speed up the preclinical development of our product portfolio in our new research laboratories,” said Vincent Charlon, PhD, CEO of Anergis.

"We see Anergis as a good example of Swiss strengths, bringing together excellent science, an experienced management team, a solid value proposition, a clear execution path and addressing a global unmet medical need," added Patrick Scherrer.

"Anergis has developed a unique technology with the potential to change the treatment paradigm of allergic patients. We look forward to further supporting the developments of the company on a global basis," said Sten Verland.

“This round of financing is an important validation of the potential of Anergis’ approach to develop a new generation of synthetic products to better serve the growing allergy market,” explained Markus Hosang.

###

About Anergis SA: Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel allergy vaccines targeting the most frequent allergies. Allergies are the most prevalent and the fastest growing chronic conditions in the industrialized world with over 300 million people affected. While short-term symptomatic treatments of allergy need to be prescribed continuously, the only curative therapy of allergy, known as “desensitization” or “Specific Immunotherapy” (SIT), is a process of induction of tolerance to the allergen that today requires 3-5 years of treatment and poses the risk of serious side effects. Based on its proprietary Contiguous Overlapping Peptides (“COPs”) technology, which Anergis acquired from the University of Lausanne, Switzerland (UNIL), the Federal Institute of Technology (EPFL) and the Centre Hospitalier Universitaire Vaudois (CHUV), the company is developing innovative SIT products containing so-called COPs that reproduce the full amino acid sequence of the allergen in separate long peptidic molecules. Anergis COPs do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Thus, COPs can safely be administered at high doses to induce tolerance to the allergen after few injections only. Studies of COPs targeting bee venom and birch pollen allergies in both animals and humans have demonstrated excellent safety (no immediate allergic reaction) and immunogenicity (production of specific antibodies and cytokines against the original allergen) of Anergis products.

Anergis SA
Chemin du Polny 34b
CH- 1066 Epalinges
Switzerland

Mr. Vincent Charlon
Tel.: +49 (0)30 2363 2768
info@anergis.ch

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anergis Closes CHF 18 Million Series A Financing Round to Develop its Innovative Allergy Vaccines and Expands its Board of Directors here

News-ID: 168502 • Views:

More Releases from Anergis SA

Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Lik …
- Study is performed at the Helmholtz Centre for Infection Research and supported by a TRANSVAC2 grant - Epalinges, Switzerland, July 09, 2020 – Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for
Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generat …
- The second-generation COP Allergy Vaccines met the preset success criteria: strong TH1 response, absence of IgE response and excellent tolerability - Anergis will raise new financing to conduct clinical trials with the second-generation COP Allergy Vaccines as soon as possible EPALINGES, Switzerland, December 13th, 2018 – Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has successfully completed the mice proof-of-concept study

More Releases for Switzerland

Switzerland Self-Storage Market 2021 is Booming Worldwide with Profiling Key Pla …
The “Switzerland Self-Storage Market” Research Report 2021-2027 is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection from industry experts and professionals. The study is a detailed document on key aspects of the markets including trends, segmentation, growth prospects, opportunities, challenges, and competitive analysis. The Switzerland self-storage
Switzerland Agriculture Market | Switzerland Agriculture Industry | Switzerland …
The Agriculture has always been of prodigious importance for Switzerland, as feeding the world’s prime population is not a calm task. The Switzerland government has been supportive the agriculture industry with a sum of policies, trying to stabilize the output and seeking techniques to ensure the division is growing healthily and sustainably. The Switzerland federal government has been decidedly supportive of the agriculture for decades, and there is extensive political
Switzerland Agriculture Market | Switzerland Agriculture Industry | Switzerland …
Switzerland Agriculture, land used for agriculture amounts to 37% of the overall space. Regarding one third of the agricultural land is found within the midlands. Pastures and meadows account for the most important a part of the complete agricultural land. Consequently, the bulk of the farms focus on stock agriculture, whereby dairy cattle farming dominate. The foremost vital land-utilization category in cultivable farming is cereals. The Swiss soils, terrain, and climate don’t
Diamond Coatings Market Demand Survey 2025| Oerlikon (Switzerland), NeoCoat SA ( …
Global Diamond Coatings Market: Overview Diamond coatings or diamond –like carbon is a type of amorphous carbon which depicts some of the usual properties of a diamond. Generally, it is use as a coatings on other materials with could draw the benefits from these traits. The global diamond coatings market is anticipated to flourish at a robust CAGR during the forecast period from 2017 to 2025. Request Sample Copy of the Report
Switzerland Beer and Cider Market 2017: Key Players – FeldschlÖsschen, Heinek …
SUMMARY WiseGuyReports published new report, titled “Switzerland Beer and Cider Market Insights” Switzerland Beer and Cider Market Insights 2017 report provides a complete overview of the Switzerland beer and cider industry structure offering a comprehensive insight into historical background trends, 2016 performance and 2017 outlook. GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2536061-switzerland-beer-and-cider-market-insights-2017 Scope Covering total market (on and off-premise) the report details - - 2011-2016 actual detailed beer consumption volume data by segment, brand, brewer, packaging and
Global Coffee Capsules Sales Market Research- Nestle Nespresso(Switzerland), Bes …
Qyresearchreports include new market research report "Global Coffee Capsules Sales Market Report 2017" to its huge collection of research reports. This business and commerce study on the global Coffee Capsules market has been freshly compiled by a group of professional market research analysts and aspires to serve a reliable business tool for the stockholders of this market. The report begins with an overview of the global Coffee Capsules market, evaluating market